-
Is maternal serum total hCG a marker of trisomy 21 in the first trimester of pregnancy?
Spencer K, Berry E, Crossley JA, Aitken DA, Nicolaides KH.
Prenat Diagn 2000;20:311-7. -
The 11-14 week scan.
Nicolaides KH, Heath V, Liao AW.
Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:581-94. -
Maternal age and gestation-specific risk for trisomy 21.
Snijders RJ, Sundberg K, Holzgreve W, Henry G, Nicolaides KH.
Ultrasound Obstet Gynecol 1999;13:167-70. -
Maternal serum S100 protein in normal and Down syndrome pregnancies.
Abraha HD, Noble PL, Nicolaides KH, Sherwood RA.
Prenat Diagn 1999;19:334-6. -
Collagen type VI gene expression in the skin of trisomy 21 fetuses.
von Kaisenberg CS, Brand-Saberi B, Christ B, Vallian S, Farzaneh F, Nicolaides KH.
Obstet Gynecol 1998;91:319-23. -
Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10-14 weeks of gestation.
Souka AP, Snijders RJ, Novakov A, Soares W, Nicolaides KH.
Ultrasound Obstet Gynecol 1998;11:391-400. -
UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation.
Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH.
Lancet 1998;352:343-6. -
Screening for fetal abnormalities in multiple pregnancies.
Sebire NJ, Nicolaides KH.
Baillieres Clin Obstet Gynaecol 1998;12:19-36. -
Outcome of chromosomally normal livebirths with increased fetal nuchal translucency at 10-14 weeks' gestation.
Brady AF, Pandya PP, Yuksel B, Greenough A, Patton MA, Nicolaides KH.
J Med Genet 1998;35:222-4. -
First trimester urine free beta hCG, beta core, and total oestriol in pregnancies affected by Down's syndrome: implications for first-trimester screening with nuchal translucency and serum free beta hCG.
Spencer K, Noble P, Snijders RJ, Nicolaides KH.
Prenat Diagn 1997;17:525-38. -
Diagnosis of fetal abnormalities at the 10-14-week scan.
Souka AP, Nicolaides KH.
Ultrasound Obstet Gynecol 1997;10:429-42. -
Maternal serum inhibin-A and free beta-hCG concentrations in trisomy 21 pregnancies at 10-14 weeks of gestation.
Noble PL, Wallace EM, Snijders RJ, Groome NP, Nicolaides KH.
BJOG 1997;104:367-71. -
Down's syndrome screening with nuchal translucency.
Nicolaides KH, Sebire NJ, Snijders RJ.
Lancet 1997;349:438. -
Screening for trisomy 21 in twin pregnancies by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation.
Sebire NJ, Snijders RJM, Hughes K, Sepulveda W, Nicolaides KH.
BJOG 1996;103:999-1003. -
Down's syndrome screeening in the UK.
Nicolaides KH, Sebire NJ, Snijders RJ, Johnson S, Reynolds TM.
Lancet 1996;347:906-7. -
Intrauterine lethality of trisomy 21 fetuses with increased nuchal translucency.
Hyett JH, Sebire NJ, Snijders RJM, Nicolaides KH.
Ultrasound Obstet Gynecol 1996;7:101-3. -
Natural history of trisomy 21 Fetuses with fetal nuchal translucency.
Pandya PP, Snijders RJM, Johnson S, Nicolaides KH.
Ultrasound Obstet Gynecol 1995;5:381-3. -
Screening for fetal trisomy 21 in the first trimester of pregnancy: maternal serum free beta-hCG and fetal nuchal translucency thickness.
Noble PL, Abraha HD, Snijders RJ, Sherwood R, Nicolaides KH.
Ultrasound Obstet Gynecol 1995;6:390-5. -
First trimester nuchal translucency and cardiac septal defects in fetuses with trisomy 21.
Hyett JA, Moscoso G, Nicolaides KH.
Am J Obstet Gynecol 1995;172:1411-3. -
Increased nuchal translucency in Trisomy 21 fetuses: Relation to narrowing of the aortic isthmus.
Hyett JA, Moscoso G, Nicolaides KH.
Hum Reprod 1995;10:3049-3051.